Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ctDNA transiting into urine is ultrashort and facilitates noninvasive liquid biopsy of HPV+ oropharyngeal cancer.
Bhambhani C, Kang Q, Hovelson DH, Sandford E, Olesnavich M, Dermody SM, Wolfgang J, Tuck KL, Brummel C, Bhangale AD, He K, Gutierrez MG, Lindstrom RH, Liu CJ, Tuck M, Kandarpa M, Mierzwa M, Casper K, Prince ME, Krauss JC, Talpaz M, Henry NL, Giraldez MD, Ramnath N, Tomlins SA, Swiecicki PL, Brenner JC, Tewari M. Bhambhani C, et al. Among authors: brummel c. JCI Insight. 2024 Feb 8;9(6):e177759. doi: 10.1172/jci.insight.177759. JCI Insight. 2024. PMID: 38516891 Free PMC article.
Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma.
Haring CT, Bhambhani C, Brummel C, Jewell B, Bellile E, Heft Neal ME, Sandford E, Spengler RM, Bhangale A, Spector ME, McHugh J, Prince ME, Mierzwa M, Worden FP, Tewari M, Swiecicki PL, Brenner JC. Haring CT, et al. Among authors: brummel c. Oncotarget. 2021 Jun 22;12(13):1214-1229. doi: 10.18632/oncotarget.27992. eCollection 2021 Jun 22. Oncotarget. 2021. PMID: 34194620 Free PMC article.
Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.
Cao Y, Haring CT, Brummel C, Bhambhani C, Aryal M, Lee C, Heft Neal M, Bhangale A, Gu W, Casper K, Malloy K, Sun Y, Shuman A, Prince ME, Spector ME, Chinn S, Shah J, Schonewolf C, McHugh JB, Mills RE, Tewari M, Worden FP, Swiecicki PL, Mierzwa M, Brenner JC. Cao Y, et al. Among authors: brummel c. Clin Cancer Res. 2022 Jan 15;28(2):350-359. doi: 10.1158/1078-0432.CCR-21-2338. Epub 2021 Oct 26. Clin Cancer Res. 2022. PMID: 34702772 Free PMC article. Clinical Trial.
Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
Bhambhani C, Sandford E, Haring CT, Brummel C, Tuck KL, Olesnavich M, Bhangale AD, Walline HM, Dermody SM, Spector ME, Chinn SB, Casper K, Mierzwa M, Swiecicki PL, Chad Brenner J, Tewari M. Bhambhani C, et al. Among authors: brummel c. Oral Oncol. 2023 Aug;143:106436. doi: 10.1016/j.oraloncology.2023.106436. Epub 2023 Jun 1. Oral Oncol. 2023. PMID: 37269557
Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.
Haring CT, Kana LA, Dermody SM, Brummel C, McHugh JB, Casper KA, Chinn SB, Malloy KM, Mierzwa M, Prince MEP, Rosko AJ, Shah J, Stucken CL, Shuman AG, Brenner JC, Spector ME, Worden FP, Swiecicki PL. Haring CT, et al. Among authors: brummel c. Cancer. 2023 Sep 15;129(18):2817-2827. doi: 10.1002/cncr.34823. Epub 2023 May 10. Cancer. 2023. PMID: 37162461
Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.
Haring CT, Brummel C, Bhambhani C, Jewell B, Neal MH, Bhangale A, Casper K, Malloy K, McLean S, Shuman A, Stucken C, Rosko A, Prince M, Bradford C, Eisbruch A, Mierzwa M, Tewari M, Worden FP, Swiecicki PL, Spector ME, Brenner JC. Haring CT, et al. Among authors: brummel c. Oral Oncol. 2021 Oct;121:105332. doi: 10.1016/j.oraloncology.2021.105332. Epub 2021 Jun 14. Oral Oncol. 2021. PMID: 34140235 Free PMC article. No abstract available.
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
Smith JD, Ludwig ML, Bhangale AD, Brummel C, Swiecicki PL, Worden FP, Chinn SB, Stucken CL, Rosko AJ, Prince MEP, Malloy KM, Casper KA, Bradford CR, Chepeha DB, Shah J, Schonewolf CA, McHugh JB, Nyati MK, Eisbruch A, Mierzwa ML, Spector ME, Brenner JC. Smith JD, et al. Among authors: brummel c. Head Neck. 2023 May;45(5):1281-1287. doi: 10.1002/hed.27344. Epub 2023 Mar 18. Head Neck. 2023. PMID: 36932871 Clinical Trial.
36 results